NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.51) by 21.57 percent. This is a 100 percent decrease over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $174.055 million which beat the analyst consensus estimate of $167.867 million by 3.69 percent. This is a 12.30 percent increase over sales of $154.994 million the same period last year.